Non-reconstructable peripheral vascular disease of the lower extremity in ten patients treated with adipose-derived stromal vascular fraction cells
Non-reconstructable peripheral vascular disease of the lower extremity in ten patients treated with adipose-derived stromal vascular fraction cells
复制标题
DOI：
10.1016/j.scr.2016.12.001
复制
发表时间：
2017-01-01
影响因子：
1.2
通讯作者：
Correa, Diego
中科院分区：
文献类型：
--
作者：
Carstens, Michael H.;Gomez, Arturo;Correa, Diego
我们提出了一系列的10例患者患有不可重建的外周血管疾病（PVD），继发于动脉硬化（AS）和/或糖尿病（DM），局部注射非扩增的自体脂肪源性基质血管成分（SVF）细胞，以增强新生血管形成和慢性伤口愈合。通过手术收获脂肪组织并进行处理，以产生异质SVF细胞，用于即时注射。腓肠肌和溃疡或伤口（如果存在）局部注射所得SVF。根据临床上的无痛截肢、伤口愈合能力随时间的变化和踝/肱指数（ABI）测量值，以及使用基于MRI的血管造影成像，评价对治疗的反应。所有患者均表现出临床改善（静息痛和跛行减轻，ABI改善），大多数（6例中的5例）患者的影像学体征显示新血管形成，评价可行。同样，6例慢性伤口中有5例愈合，无需进一步手术干预。该系列强调了在护理点处理的非扩增脂肪来源的异质SVF细胞群的效用，以治疗终末期PVD患者作为缓解或截肢的替代方案。(C)2016由Elsevier B. V.发布这是CC BY-NC-ND许可下的开放获取文章。
We present a series of ten patients with non-reconstructable peripheral vascular disease (PVD), secondary to arteriosclerosis (AS) and/or diabetes mellitus (DM), treated with local injection of non-expanded autologous, adipose-derived stromal vascular fraction (SVF) cells for the purposes of enhancing neovascularization and chronic wound healing. Adipose tissue was surgically harvested and processed to yield the heterogeneous SVF cells for immediate point-of-care injection. The gastrocnemius muscles and ulcers or wounds where present were locally injected with the resulting SVF. Response to treatment was evaluated both clinically based on pain-free ambulation, wound healing capacity over time and ankle/brachial index (ABI) measurements, and by imaging using MRI-based angiography. All patients exhibited clinical improvement (reduction in rest pain and claudication and improvements in ABI), with imaging signs of neovascularization in the majority (5 of 6) of patients in whom the evaluation was feasible. Similarly, 5 of 6 chronic wounds healed without further surgical intervention. This series highlights the utility of non-expanded adipose-derived heterogeneous SVF cell population processed at the point-of-care, to treat patients with end-stage PVD as an alternative to palliation or amputation. (C) 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license.